[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371212-105":59,"doc-detail-371212-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","functional-genomics-pipeline-identifies-crl4-inhibition-for-the-treatment-of-ovarian-cancer","Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer","","Background: The goal of precision oncology is to match therapies to vulnerable tumor dependencies. This research article presents a functional genomics pipeline that identifies CRL4 inhibition as a treatment-relevant vulnerability in ovarian cancer. CRL4 inhibition triggers activation of mitogen-activated protein kinase signaling, supported by RNA sequencing, proteomics, and phosphoproteomics. Combination strategies simultaneously targeting CRL4 and the CRL4 inhibitor-induced survival signaling improve ovarian cancer sensitivity to therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/functional-genomics-pipeline-identifies-crl4-inhibition-for-the-treatment-of-ovarian-cancer/371212/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/functional-genomics-pipeline-identifies-crl4-inhibition-for-the-treatment-of-ovarian-cancer/371212.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What vulnerability does the pipeline identify for ovarian cancer treatment?","Question",{"text":112,"@type":113},"The pipeline identifies CRL4 inhibition as a treatment-relevant vulnerability for ovarian cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does CRL4 inhibition affect cellular signaling?",{"text":117,"@type":113},"CRL4 inhibition induces activation of mitogen-activated protein kinase signaling, as identified using RNA sequencing, proteomics, and phosphoproteomics.",{"name":119,"@type":110,"acceptedAnswer":120},"Why do combination treatments targeting CRL4 and survival signaling help?",{"text":121,"@type":113},"Inhibitor combinations that target both CRL4 and the CRL4 inhibitor-induced survival signaling enhance ovarian cancer sensitivity to treatment.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371212,1790270768,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","DOI: 10.1002/ctm2.70078  \nRESEARCH ARTICLE  \nFunctional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer  \nSally E. Claridge1,2, 3,4, 5   Shalini Nath1,2  Anneliese Baum3,4  Richard Farias3, 4 Julie-Ann Cavallo3, 4  Nile M. Rizvi3,4  Lamberto De Boni1,2, 3,4, 5  Eric Park3, 4  Genesis Lara Granados3, 4  Matthew Hauesgen3, 4  Ruben Fernandez-Rodriguez4, 5  \nEda Nur Kozan2, 6  Evgeny Kanshin7, 8 Kenneth Wu4  Beatrix Ueberheide7, 8, 11 Fred R. Hirsch5, 12, 13  Robert J. DeVita8, 9  \nKhoi Q. Huynh9, 10  Peng-Jen Chen9, 10   Juan Miguel Mosquera2, 6   \n Olivier Elemento2, 14, 15  Chantal Pauli16  \nZhen-Qiang Pan3  Benjamin D. Hopkins1,2  \n1 Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York, USA  \n2 Englander Institute for Precision Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York, USA  \n3 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA  \n4 Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA  \n5Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA  \n6 Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA  \n7 Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, New York, USA  \n8 Proteomics Laboratory, New York University School of Medicine, New York, New York, USA  \n9 Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA  \n10 Drug Discovery Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA 11 Department of Neurology, New York University Grossman School of Medicine, New York, New York, USA  \n12 Department of Medicine, Hematology, and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA  \n13 Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA  \n14 Institute for Computational Biomedicine, Weill Cornell Medicine, New York, New York, USA  \n15 Clinical and Translational Science Center, Weill Cornell Medicine, New York, New York, USA  \n16 Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland  \nCorrespondence  \nBenjamin D. Hopkins, Department of Physiology and Biophysics, Weill Cornell Medicine, New York, 10021 New York, USA.  \n[Email:](Email: beh2020@med.cornell.edu)[ beh2020@med.cornell.edu](Email: beh2020@med.cornell.edu)  \nGraphical Abstract  \nClin. Transl. Med. 2025;15:e70078 .  \n[https://doi.org/10.1002/ctm2.70078](https://doi.org/10.1002/ctm2.70078)  \n[wileyonlinelibrary.com/journal/ctm2](wileyonlinelibrary.com/journal/ctm2)  \nCLARIDGE et al.  \n∙ A precision medicine pipeline identifies ovarian cancer sensitivity to CRL4 inhibitors.  \n∙ CRL4 inhibition induces activation of mitogen-activated protein kinase signalling as identified by RNA sequencing, proteomics, and phosphoproteomics.  \n∙ Inhibitor combinations that target both CRL4 and this CRL4 inhibitorinduced survival signalling enhance ovarian cancer sensitivity to treatment.  \nDOI: 10.1002/ctm2.70078  \nRESEARCH ARTICLE  \nFunctional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer  \nSally E. Claridge1,2, 3,4, 5   Shalini Nath1,2  Anneliese Baum3,4  Richard Farias3, 4 Julie-Ann Cavallo3, 4  Nile M. Rizvi3,4  Lamberto De Boni1,2, 3,4, 5  Eric Park3, 4  Genesis Lara Granados3, 4  Matthew Hauesgen3, 4  Ruben Fernandez-Rodriguez4, 5  \nEda Nur Kozan2, 6  Evgeny Kanshin7, 8 Kenneth Wu4  Beatrix Ueberheide7, 8, 11 Fred R. Hirsch5, 12, 13  Robert J. DeVita8, 9  \nKhoi Q. Huynh9, 10  Peng-Jen Chen9, 10   Juan Miguel Mosquera2, 6   \n Olivier Elemento2, 14, 15  Chantal Pauli16  \nZhen-Qiang Pan3  Benjamin D. Hopkins1,2  \n1 Department of Physiology and Biophysics, Weill Cornell Medicine, New York, New York, U","cbCaidfrqOjR7OYR","https://ap.wps.com/l/cbCaidfrqOjR7OYR","pdf",6823690,26,"English","# Graphical Abstract\n## Precision medicine pipeline and ovarian cancer sensitivity\n## CRL4 inhibition and signaling activation\n## Combination targeting CRL4 and survival signaling","[{\"question\":\"What vulnerability does the pipeline identify for ovarian cancer treatment?\",\"answer\":\"The pipeline identifies CRL4 inhibition as a treatment-relevant vulnerability for ovarian cancer.\"},{\"question\":\"How does CRL4 inhibition affect cellular signaling?\",\"answer\":\"CRL4 inhibition induces activation of mitogen-activated protein kinase signaling, as identified using RNA sequencing, proteomics, and phosphoproteomics.\"},{\"question\":\"Why do combination treatments targeting CRL4 and survival signaling help?\",\"answer\":\"Inhibitor combinations that target both CRL4 and the CRL4 inhibitor-induced survival signaling enhance ovarian cancer sensitivity to treatment.\"}]","Functional genomics pipeline identifies CRL4 inhibition for the treatment of ovarian cancer | PDF",1790191530,66,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3e40da2df43fd44dfde5d359235d4c76.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b94a28ab7d2ff143998aa4b70f005a75.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/50a9838d1d821f752afbe1dfd5281a97.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a517f1331aab658525291bc12b3b0cf1.webp",980,1287]